Sanofi and JHL Biotech have entered an agreement to expand their presence and develop modern therapies for patients in China.
According to the agreement, Sanofi will acquire all rights for the proposed biosimilar of Rituximab and other pipeline products from JHL Biotech, while the latter will be responsible for the development, registration and manufacturing of the products.
Sanofi will pay up to $326m in milestone payments and sales royalties to JHL Biotech and retain commercialisation rights to the products in China.
Breckenridge Pharmaceuticals and Gland Pharma have entered a multi-product marketing agreement.
According to the agreement, the former will be responsible to market and distribute seven injectable products in the US market.
The agreement enables Breckenridge to expand its injectable product portfolio.
VBI Vaccines has completed the private placement of the debt financing, which has been subscribed to by Perceptive Advisors.
The company has raised $13m from the offering and intends to use the funds to increase the working capital and general corporate purposes.
Bluebird Bio has announced the underwritten public offering of 3.2 million of its common stock shares.
The company expects to raise gross proceeds of $294.9m through the offering, which is expected to be completed by 12 December.
Goodwin Procter is acting as the legal advisor for the offering.
The company plans to use the funds to further advance the development and clinical studies of the products for multiple myeloma, for commercial launch of LentiGlobin in Europe, and for other general corporate purposes.
Ixchelsis has raised $12m in a venture financing round led by Pfizer Venture Investments and TVM Life Sciences Ventures VII.
The company plans to invest the funds to advance the clinical study IX-01 in patients with severe premature ejaculation.